Protagenic Therapeutics 주식 (NASDAQ: PTIX)

에 대한 최신 뉴스 Protagenic Therapeutics (NASDAQ:PTIX) 주식

Protagenic Therapeutics

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics Inc

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
The Dow traded up 0.40% to 42,825.71 while the NASDAQ rose 0.02% to 19,215.06. The S&amp;P 500 also rose, gaining, 0.13% to 5,965.84.
Check This Out: <a href="https://www.benzinga.com/25/05/45489465/top-3-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 3 Tech And Telecom Stocks That May Rocket Higher This Month</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.1% on Monday.
In trading on Monday, energy stocks dipped by 1.5%.
Top Headline
Global Ship Lease, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) reported upbeat results for the first quarter on Monday.
The company posted quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.31 per share. The company reported quarterly sales of $190.97 million which beat the analyst consensus estimate of $175.23 million.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) shares shot up 188% to $0.5351 after the company announced the launch of Bitcoin treasury reserve strategy. The company said it is exploring up to $100 million capital raise to acquire Bitcoin.</li>
<li>Shares of Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) got a boost, surging 163% to $7.96 after the company entered a business combination with Phytanix</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares were also up, gaining 8% to $7.29 after the company provided FY25, 2026, and 2027 R&amp;D and SG&amp;A expense guidance. The FDA gave its conditional approval to its COVID-19 vaccine, targeting specific populations under particular conditions.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) shares dropped 9% to $6.08 after the company reported a first-quarter revenue miss.</li>
<li>Shares of Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) were down 10% to $11.64. Quantum Computing, last week, reported better-than-expected first-quarter EPS results.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) was down, falling 10% to $12.01.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $62.51 while gold traded up 1.4% at $3,233.
Silver traded up 0.2% to $32.410 on Monday, while copper rose 1% to $4.6390.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.20%, while Spain's IBEX 35 Index rose 0.06%. London's FTSE 100 fell 0.14%, Germany's DAX 40 gained 0.28% and France's CAC 40 slipped 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei falling 0.68%, Hong Kong's Hang Seng Index declining 0.05%, China's Shanghai Composite Index falling 0.004% and India's BSE Sensex declining 0.33%.
Economics
The CB Leading Index fell 1% month-over-month in April.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Intraday Update

Markets

Trading Ideas

ACHR

FAAS

GILT

NVAX

PTIX

QUBT

Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 286.8% to $11.72 during Monday's regular session. The company's market cap stands at $6.3 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 56.96% to $0.01. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 30.83% to $1.57. The market value of their outstanding shares is at $21.6 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares rose 27.17% to $0.29. The market value of their outstanding shares is at $15.2 million. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares increased by 23.2% to $1.85. The company's market cap stands at $200.3 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock moved upwards by 20.8% to $8.13. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock fell 19.2% to $1.28 during Monday's regular session. The company's market cap stands at $168.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares fell 16.67% to $0.35. The company's market cap stands at $2.0 million. </li>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock fell 15.4% to $0.51. The market value of their outstanding shares is at $72.2 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 13.53% to $0.75. The market value of their outstanding shares is at $3.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 12.81% to $342.68. The market value of their outstanding shares is at $4.4 billion. </li>
<li>Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) stock declined by 11.1% to $16.79. The market value of their outstanding shares is at $1.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLT

HCTI

LQDA

MTNB

PRME

PSTV

SXTC

TNGX

12 Health Care Stocks Moving In Monday's Intraday Session

Shares of Protagenic Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) surged 306% to $12.32 Monday morning following news of a definitive all-stock <a href="https://www.benzinga.com/pressreleases/25/05/ac45490560/protagenic-therapeutics-and-phytanix-announce-business-combination-to-form-neuroactive-biopharmac">merger agreement</a> with Phytanix Bio.
What To Know: The combined company, to be named Phytanix, will focus on treatments for central nervous system and stress-related disorders, boasting five preclinical assets and one clinical-stage peptide (PT-00114) already in the BLA pathway.
Phytanix's pipeline includes PHYX-001, a potassium channel modulator akin to XEN1101, and cannabinoid- and stilbenoid-based compounds targeting CNS, cardiometabolic, and anticonvulsant indications. 
Under the deal, Phytanix shareholders received a mix of Protagenic common and preferred shares, plus warrants, in exchange for their equity. Post-merger, Phytanix shareholders will own 65% of the combined entity on a fully diluted basis.
The transaction closed May 16, with share conversions subject to Nasdaq stockholder approval.
Read Also: <a href="https://www.benzinga.com/general/space/25/05/45493132/whats-going-on-with-virgin-galactic-stock">What&#8217;s Going On With Virgin Galactic Stock?</a>
<h2 class="wp-block-heading">How To Buy PTIX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Protagenic Therapeutics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PTIX has a 52-week high of $26.18 and a 52-week low of $2.35.

Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger

Protagenic Therapeutics Shares Resume Trade

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Monday.
Following the market opening Monday, the Dow traded down 0.48% to 42,450.71 while the NASDAQ fell 0.88% to 19,041.91. The S&amp;P 500 also fell, dropping, 0.79% to 5,911.48.
Check This Out: <a href="https://www.benzinga.com/25/05/45489465/top-3-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 3 Tech And Telecom Stocks That May Rocket Higher This Month</a>
Leading and Lagging Sectors Health care shares slipped by just 0.2% on Monday.
In trading on Monday, energy stocks dipped by 2.2%.
Top Headline
ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) reported better-than-expected earnings for the first quarter.
The company posted quarterly earnings of $2.45 per share which beat the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $2.01 billion which beat the analyst consensus estimate of $1.85 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) shares shot up 209% to $0.5739 after the company announced the launch of Bitcoin treasury reserve strategy. The company said it is exploring up to $100 million capital raise to acquire Bitcoin.</li>
<li>Shares of Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) got a boost, surging 164% to $8.00 after the company entered a business combination with Phytanix</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares were also up, gaining 79% to $0.0141.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares dropped 62% to $0.0029.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 34% to $0.1833 after jumping 228% on Friday.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) was down, falling 35% to $0.1869.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $62.20 while gold traded up 1.4% at $3,233.10.
Silver traded up 0.3% to $32.465 on Monday, while copper rose 1.1% to $4.6460.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, while Spain's IBEX 35 Index fell 0.1%. London's FTSE 100 fell 0.5%, Germany's DAX 40 slipped 0.1% and France's CAC 40 slipped 0.7% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei falling 0.68%, Hong Kong's Hang Seng Index declining 0.05%, China's Shanghai Composite Index falling 0.004% and India's BSE Sensex declining 0.33%.
Economics
The CB Leading Index will be released today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Commodities

AFMD

ZAPP

Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 110.1% to $0.02 during Monday's pre-market session. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 78.48% to $5.41. The market value of their outstanding shares is at $2.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 41.66% to $1.87. The company's market cap stands at $10.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 34.84% to $0.01. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) stock increased by 32.59% to $1.79. The company's market cap stands at $64.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares moved upwards by 25.04% to $1.5. The market value of their outstanding shares is at $20.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 17.6% to $2.01 during Monday's pre-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 14.78% to $6.69. The market value of their outstanding shares is at $44.0 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock fell 11.12% to $0.8. The company's market cap stands at $64.7 million. The company's, H1 earnings came out 2 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 10.51% to $4.09. The market value of their outstanding shares is at $22.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock fell 8.78% to $3.64. The market value of their outstanding shares is at $19.4 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 7.89% to $0.21. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMP

BCLI

FBRX

IMAB

KLTO

LPCN

MYNZ

PLRZ

STSS

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Protagenic Therapeutics shares are trading higher after the company entered a business combination with Phytanix

Structure of Combination
Under the terms of the Exchange Agreement, the Company, in exchange for all of the outstanding shares of Phytanix Bio, issued on a pro rata basis to each of the common stockholders of Phytanix Bio, an aggregate of (A) 117,690 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), which shares represent a number equal to no more than 19.99% of the outstanding shares of Common Stock as of immediately before the closing on May 16, 2025, (B) 5,705 shares of the Company's Series C Convertible Preferred Stock, par value $0.000001 per share (the "Series C"), and (C) 950,000 shares of the Company's Series C-1 Convertible Preferred Stock, par value $0.000001 per share (the "Series C-1"). In addition, in exchange for all of the outstanding preferred stock of Phytanix Bio, the Company issued on a pro rata basis to each of PHX's preferred stockholders an aggregate of (i) 20,000 shares of Series D Preferred Stock, par value $0.000001 per share of the Company (the "Series D" together with the Series C and Series C-1, the "Preferred Stock"), and (ii) common stock purchase warrants to purchase up to 715,493 shares of common stock (the "Warrants"). The issuance of the shares of Common Stock, the Preferred Stock, and the Warrants occurred on May 16, 2025. Each share of Preferred Stock is convertible into one of common stock, subject to certain conditions described in the Exchange Agreement.
As calculated on a fully diluted basis, post-Combination pre-financing ownership will be approximately 35% for the pre-Combination stockholders of the Company and approximately 65% for Phytanix Bio stockholders.
The issuance of shares of common stock upon conversion of the Preferred Stock and exercise of the Warrants issued in the Combination shall be subject to stockholder approval in compliance with the rules of the Nasdaq Stock Market.

As Calculated On A Fully Diluted Basis, Post-Combination Pre-Financing Ownership Will Be Approximately 35% For The Pre-Combination Stockholders Of The Company And Approximately 65% For Phytanix Bio Stockholders.

Protagenic Therapeutics And Phytanix Enter Business Combination In All-Stock Transaction

Shares of Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose sharply in today's pre-market after the company reported better-than-expected first-<a href="https://in.benzinga.com/news/earnings/25/05/45456393/quantum-computing-inc-reports-q1-earnings-shares-move-higher-after-hours">quarter EPS results</a>.
Quantum Computing reported first-quarter revenue of $39,000, missing analyst estimates of $100,000, according to Benzinga Pro. The company reported first-quarter earnings of 11 cents per share, beating estimates for a loss of seven cents per share.
Quantum Computing shares jumped 11.6% to $10.32 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) surged 56.7% to $13.90 in pre-market trading after the company reported a year-over-year increase in first-quarter revenue results.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) rose 51.1% to $2.75 in pre-market trading after the company reported third-quarter results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) gained 29% to $4.32 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) gained 28.8% to $0.3457 in pre-market trading after dipping 62% on Thursday. The company reported a year-over-year increase in third-quarter EPS results.</li>
<li>Kalaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) jumped 21.5% to $4.30 in pre-market trading after gaining around 5% on Thursday.</li>
<li>Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) surged 12.9% to $0.79 in pre-market trading after reporting first-quarter results.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) climbed 12.2% to $3.50 in pre-market trading after declining around 5% on Thursday. The company recently reported first-quarter financial results.</li>
<li>Satellogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) gained 9.2% to $5.09 in pre-market trading. On Tuesday, the company reported a year-over-year increase in first-quarter sales results.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) rose 6.3% to $67.70 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 67.8% to $0.0121 in pre-market trading after dipping 83% on Thursday.</li>
<li>Origin Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) fell 28.1% to $0.4655 in today's pre-market trading after the company reported a year-over-year decrease in first-quarter financial results and cut its FY26 sales guidance below estimates.</li>
<li>Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) shares dipped 26.2% to $98.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results, issued second-quarter guidance below estimates, and cut its FY25 guidance.</li>
<li>LogProstyle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGPS#NASDAQ">LGPS</a>) fell 24.6% to $2.05 in pre-market trading after dipping 55% on Thursday.</li>
<li>Click Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares tumbled 26% to $0.5250 in pre-market trading. Click Holdings shares jumped 154% on Thursday after the company announced it signed a cooperation agreement with Flash Mutual Technology.</li>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares fell 23.7% to $0.2022 in pre-market trading after gaining 60% on Thursday.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) dipped 22.1% to $45.52 in pre-market trading after the company issued FY26 sales guidance below estimates.</li>
<li>CISO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) fell 21.3% to $0.9527 in pre-market trading after dipping 15% on Thursday.</li>
<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) declined 15.2% to $17.94 in pre-market trading. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 5.8% to $164.65 in pre-market trading. Applied Materials reported better-than-expected earnings for its second quarter, while sales missed estimates. Applied Materials said it expects third-quarter revenue of $7.2 billion, plus or minus $500 million, versus estimates of $7.19 billion. The company expects third-quarter adjusted earnings to be between $2.15 and $2.55 per share, versus estimates of $2.32 per share.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45435278/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

IXHL

KLRS

LGPS

ORGN

SATL

SPCE

TSSI

TVTX

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Protagenic Therapeutics shares are trading lower. The company reported Q1 financial results.

Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) reported quarterly losses of $(2.75) per share. This is a 49.45 percent increase over losses of $(5.44) per share from the same period last year.

Protagenic Therapeutics Q1 EPS $(2.75) Up From $(5.44) YoY

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 26.8% to $1.8 during Tuesday's after-market session. The company's market cap stands at $7.8 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock moved upwards by 17.85% to $0.2. The company's market cap stands at $5.1 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares moved upwards by 9.09% to $0.51. The company's market cap stands at $24.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 9.03% to $0.59. The company's market cap stands at $3.5 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) stock rose 7.69% to $4.2. The market value of their outstanding shares is at $32.6 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 7.29% to $0.44. The company's market cap stands at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 17.7% to $0.25 during Tuesday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) shares decreased by 16.43% to $1.17. The company's market cap stands at $33.7 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 8.38% to $0.2. The market value of their outstanding shares is at $1.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 7.66% to $0.24. The company's market cap stands at $12.5 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 7.55% to $2.82. The market value of their outstanding shares is at $12.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 7.37% to $0.02. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AKTX

ASBP

BCDA

CYCC

GCTK

LGMK

MNDR

NCNA

RADX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 23.5% to $1.26 during Monday's after-market session. The company's market cap stands at $17.3 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock increased by 21.05% to $0.28. The company's market cap stands at $24.7 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares moved upwards by 8.08% to $1.46. The company's market cap stands at $28.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 7.65% to $0.23. The company's market cap stands at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 7.63% to $0.72. The market value of their outstanding shares is at $4.7 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 7.03% to $0.24. The company's market cap stands at $1.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares declined by 15.7% to $3.49 during Monday's after-market session. The company's market cap stands at $53.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares decreased by 11.42% to $0.62. The company's market cap stands at $1.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock decreased by 10.04% to $260.0. The market value of their outstanding shares is at $7.9 billion. The company's, Q1 earnings came out today. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) shares fell 9.19% to $5.24. The market value of their outstanding shares is at $7.7 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares declined by 7.57% to $1.1. The company's market cap stands at $2.7 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares declined by 6.8% to $0.41. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ANVS

CLDI

ENVB

MEDP

PRPO

XAIR

YCBD

ZVSA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 76.0% to $0.04 during Monday's pre-market session. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares increased by 37.36% to $5.0. The company's market cap stands at $225.5 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 32.2% to $4.31. The company's market cap stands at $382.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 27.6% to $0.16. The market value of their outstanding shares is at $4.7 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares rose 26.52% to $1.04. The market value of their outstanding shares is at $3.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 22.3% to $0.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 17.4% to $6.21 during Monday's pre-market session. The company's market cap stands at $581.3 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 16.45% to $0.79. The market value of their outstanding shares is at $126.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares declined by 14.18% to $0.95. The company's market cap stands at $4.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 12.67% to $1.24. The company's market cap stands at $3.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 11.7% to $0.26. The company's market cap stands at $1.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock declined by 11.61% to $2.21. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTL

GYRE

IRWD

KTTA

MSPR

THRD

VERV

VRAX

Longevity Health Holdings, Inc. - Common Stock

XAGE

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 55.6% to $0.24 during Tuesday's after-market session. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

AEMD

ANIX

ATNF

NAOV

NAYA

REVB

SLRX

VERO

VINC

WORX

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 190.8% to $8.55 during Tuesday's pre-market session. The company's market cap stands at $6.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 32.42% to $0.58. The market value of their outstanding shares is at $2.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 32.33% to $2.38. The company's market cap stands at $3.5 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 27.36% to $2.67. The company's market cap stands at $13.1 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock increased by 22.32% to $3.89. The company's market cap stands at $8.6 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares increased by 20.07% to $27.51. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 51.2% to $3.66 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock decreased by 46.37% to $1.4. The market value of their outstanding shares is at $109.6 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 30.25% to $8.05. The company's market cap stands at $209.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.02% to $0.7. The company's market cap stands at $8.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.44% to $0.27. The company's market cap stands at $2.0 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock decreased by 16.17% to $1.09. The market value of their outstanding shares is at $52.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CVRX

PCRX

PHLT

STTK

SXTP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock increased by 165.7% to $9.38 during Monday's pre-market session. The company's market cap stands at $5.1 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock increased by 37.28% to $9.5. The market value of their outstanding shares is at $889.3 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares moved upwards by 35.31% to $1.59. The market value of their outstanding shares is at $3.0 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 26.07% to $4.5. The market value of their outstanding shares is at $165.9 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock moved upwards by 19.98% to $0.81. The company's market cap stands at $51.3 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) shares increased by 18.63% to $0.81. The company's market cap stands at $65.2 million. As per the press release, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 37.0% to $0.15 during Monday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares decreased by 29.45% to $13.01. The market value of their outstanding shares is at $466.6 million. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) stock declined by 22.45% to $6.46. The company's market cap stands at $422.2 million. </li>
<li>Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) shares decreased by 21.48% to $28.01. The market value of their outstanding shares is at $79.9 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 20.64% to $0.31. The company's market cap stands at $2.2 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) stock fell 20.64% to $0.5. The company's market cap stands at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBLL

CNTB

KEQU

MOLN

QNRX

THAR

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 23.7% to $4.23 during Friday's after-market session. The market value of their outstanding shares is at $2.3 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares moved upwards by 18.0% to $0.34. The company's market cap stands at $8.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 12.82% to $0.44. The market value of their outstanding shares is at $2.7 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 12.2% to $1.74. The company's market cap stands at $2.5 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 10.29% to $0.75. The market value of their outstanding shares is at $60.6 million. The company's, FY earnings came out yesterday. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 8.62% to $1.26. The market value of their outstanding shares is at $7.1 million. The company's, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 17.9% to $0.79 during Friday's after-market session. The market value of their outstanding shares is at $9.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 14.19% to $0.33. The market value of their outstanding shares is at $2.4 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares fell 10.41% to $0.15. The company's market cap stands at $24.9 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares declined by 9.44% to $0.48. The market value of their outstanding shares is at $44.0 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.57% to $0.21. The company's market cap stands at $3.9 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock fell 7.47% to $1.24. The company's market cap stands at $8.9 million. The company's, Q4 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPHI

PIII

POAI

SHPH

SNSE

VRCA

12 Health Care Stocks Moving In Friday's After-Market Session

Biotech

Press Releases

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Legal

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

Contracts

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

Comments

Protagenic Therapeutics

뉴스

에 대한 최신 뉴스 Protagenic Therapeutics (NASDAQ:PTIX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌